- Home
- JNVR vs NTBL Comparison
JNVR vs NTBL Comparison
Compare JNVR & NTBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- NTBL
- Stock Information
- Founded
- JNVR 2018
- NTBL 2000
- Country
- JNVR United States
- NTBL United States
- Employees
- JNVR N/A
- NTBL N/A
- Industry
- JNVR Finance: Consumer Services
- NTBL Biotechnology: Pharmaceutical Preparations
- Sector
- JNVR Finance
- NTBL Health Care
- Exchange
- JNVR Nasdaq
- NTBL Nasdaq
- Market Cap
- JNVR N/A
- NTBL 4.6M
- IPO Year
- JNVR 2023
- NTBL N/A
- Fundamental
- Price
- JNVR $0.55
- NTBL $0.25
- Analyst Decision
- JNVR
- NTBL Buy
- Analyst Count
- JNVR 0
- NTBL 2
- Target Price
- JNVR N/A
- NTBL $5.00
- AVG Volume (30 Days)
- JNVR 21.7K
- NTBL 8.1M
- Earning Date
- JNVR 11-12-2024
- NTBL 11-12-2024
- Dividend Yield
- JNVR N/A
- NTBL N/A
- EPS Growth
- JNVR N/A
- NTBL N/A
- EPS
- JNVR N/A
- NTBL N/A
- Revenue
- JNVR $1,786,085.00
- NTBL $313,000.00
- Revenue This Year
- JNVR N/A
- NTBL N/A
- Revenue Next Year
- JNVR N/A
- NTBL N/A
- P/E Ratio
- JNVR N/A
- NTBL N/A
- Revenue Growth
- JNVR N/A
- NTBL 3812.50
- 52 Week Low
- JNVR $0.42
- NTBL $0.22
- 52 Week High
- JNVR $1.84
- NTBL $4.24
- Technical
- Relative Strength Index (RSI)
- JNVR 49.64
- NTBL 35.14
- Support Level
- JNVR $0.49
- NTBL $0.28
- Resistance Level
- JNVR $0.62
- NTBL $0.37
- Average True Range (ATR)
- JNVR 0.06
- NTBL 0.06
- MACD
- JNVR -0.00
- NTBL -0.01
- Stochastic Oscillator
- JNVR 58.69
- NTBL 6.26
About NTBL Notable Labs Ltd.
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.